TSG101 Antibody

What is TSG101 and what cellular functions does it regulate?

TSG101 (Tumor Susceptibility Gene 101) is a multifunctional protein of approximately 44-45 kDa that serves as a critical component of the ESCRT-I (Endosomal Sorting Complex Required for Transport) complex. It regulates multiple cellular processes including:

• Intracellular vesicular trafficking

• Sorting of ubiquitinated cargo proteins into multivesicular bodies (MVBs)

• Mediating associations between ESCRT-0 and ESCRT-I complexes

• Completion of cytokinesis (requiring interaction with CEP55)

• Negative regulation of cell growth

• Facilitation of viral budding through interaction with viral proteins containing P-[ST]-A-P late-budding motifs

• Exosomal release of proteins such as SDCBP, CD63, and syndecan

The protein is expressed in multiple tissues including heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas .

What are the recommended applications for TSG101 antibodies?

Based on extensive validation across multiple sources, TSG101 antibodies are suitable for the following applications:

How do I select the optimal fixation method for TSG101 immunostaining?

The selection of fixation method significantly impacts TSG101 epitope accessibility:

• Paraformaldehyde (4%): Most commonly used and recommended for preserving TSG101 antigenicity in both cells and tissues. Optimal fixation time is 10-15 minutes at room temperature for cultured cells .

• Methanol fixation: Can be advantageous for certain epitopes but may disrupt some TSG101 conformational epitopes. If using methanol, pre-chill to -20°C and fix for 10 minutes .

• Acetone fixation: Generally not recommended as it can lead to protein extraction and reduced signal intensity.

• Antigen retrieval: For paraffin-embedded tissues, heat-induced epitope retrieval using citrate buffer (pH 6.0) is recommended prior to TSG101 immunostaining .

Empirical testing of multiple fixation methods is advised when establishing a new protocol with a particular TSG101 antibody.

How can I optimize Western blot detection of TSG101 in exosome preparations?

Exosome-derived TSG101 detection requires specific optimizations:

• Sample preparation:

  • Use ultracentrifugation (100,000-120,000 × g for 70-120 minutes) or commercial exosome isolation kits

  • Lyse exosomes in RIPA buffer supplemented with protease inhibitors

  • Load 10-30 μg of exosomal protein per lane

• Electrophoresis and transfer conditions:

  • Use 10-12% SDS-PAGE gels

  • Transfer to PVDF membranes at 100V for 60-90 minutes in cold transfer buffer containing 20% methanol

• Antibody dilution and incubation:

  • Primary TSG101 antibody: 1:500-1:2000 dilution (optimum usually 1:1000)

  • Incubate overnight at 4°C with gentle rocking

  • Secondary antibody: 1:5000-1:10000, incubate for 1 hour at room temperature

• Controls:

  • Include cell lysate positive control

  • Include exosome-depleted supernatant as negative control

  • Consider using Alix or CD63 as additional exosomal markers for validation

• Detection:

  • Enhanced chemiluminescence (ECL) systems with 30-second to 2-minute exposure typically provide optimal results

  • The expected molecular weight of TSG101 is 44-45 kDa

What are the critical considerations when using TSG101 as an exosomal marker?

TSG101 serves as a valuable marker for exosome characterization but requires careful implementation:

• Multiple marker approach: Use TSG101 in conjunction with other exosomal markers (CD63, CD9, CD81, Alix) for comprehensive characterization. No single marker is sufficient for definitive exosome identification .

• Sample purity assessment: Evaluate potential contamination from cellular debris, protein aggregates, and other extracellular vesicle subtypes.

• Negative controls: Include non-exosomal markers (calnexin, GM130, cytochrome C) to confirm absence of contaminating organelles.

• Quantitative considerations: TSG101 levels vary between different cell types and physiological/pathological conditions, necessitating proper normalization .

• Context interpretation: TSG101 is enriched in but not exclusive to exosomes. It can also be found in other extracellular vesicle subtypes and intracellular compartments .

• User reviews: Researchers report successful use of TSG101 antibodies for exosome detection across multiple studies, confirming its utility as a reliable marker when properly implemented .

How does subcellular localization of TSG101 change throughout the cell cycle?

TSG101 exhibits dynamic cell cycle-dependent localization that impacts experimental design and interpretation:

• G0/Serum-starved cells: Limited amounts of TSG101, predominantly nuclear localization .

• G1 phase: Prominent nuclear localization (both diffuse and in discrete foci) with asymmetric perinuclear cytoplasmic localization .

• S phase: Progressive redistribution with increasing cytoplasmic presence.

• G2/M phase: Complex redistribution with potential association with microtubular structures.

• M phase/Cytokinesis: Localization to the midbody, critical for completion of cytokinesis.

Importantly, different TSG101 antibodies may detect specific subcellular pools based on epitope accessibility. Some epitopes may be masked in certain subcellular compartments due to protein-protein interactions. For example, antibodies against the C-terminal domain failed to detect microtubule-associated TSG101, suggesting epitope masking .

This dynamic localization pattern necessitates careful consideration of cell synchronization status when performing TSG101 immunostaining experiments.

What experimental approaches can resolve discrepancies in TSG101 detection between different antibodies?

When facing discrepancies between different TSG101 antibodies, consider the following systematic approach:

• Epitope mapping comparison:

  • N-terminal domain antibodies may detect different TSG101 pools than C-terminal domain antibodies

  • Different epitopes may be differentially accessible in various subcellular compartments or protein complexes

• Validation experiments:

  • siRNA/shRNA knockdown to confirm specificity

  • Use of TSG101-overexpressing cells as positive control

  • Peptide competition assays to confirm epitope specificity

  • Comparison with recombinant TSG101 standards of known concentration

• Cross-validation with alternative methods:

  • mRNA expression analysis (RT-PCR, RNA-seq)

  • Mass spectrometry validation

  • Multiple antibodies targeting different epitopes

• Optimization for specific applications:

  • Different antibody clones may perform optimally in different applications

  • For example, clone 4A10 might excel in ICC while C-2 may be superior for WB

• Technical considerations:

  • Different antibody dilutions may be required (typically 1:500-1:2000)

  • Blocking conditions may need adjustment (5% BSA often preferred over milk for phosphorylated epitopes)

  • Incubation times and temperatures may require optimization

How can TSG101 antibodies be effectively used to study viral budding mechanisms?

TSG101 antibodies are valuable tools for investigating viral budding mechanisms due to TSG101's critical role in this process:

• Interaction studies:

  • Co-immunoprecipitation using TSG101 antibodies can capture viral proteins containing P-[ST]-A-P late-budding motifs

  • Proximity ligation assays using TSG101 antibodies can visualize interactions with viral proteins in situ

• Localization studies:

  • Use TSG101 antibodies in combination with viral protein immunostaining to track recruitment to budding sites

  • Live-cell imaging with fluorescently tagged TSG101 antibody fragments to monitor dynamics

• Functional interference:

  • Microinjection of TSG101 antibodies can block TSG101 function in viral budding

  • Controls should include non-immune IgG and antibodies targeting irrelevant ESCRT components

• Quantitative budding assays:

  • Western blot for TSG101 incorporation into viral particles

  • Immunogold electron microscopy using TSG101 antibodies to visualize incorporation into budding virions

• Experimental considerations:

  • Use multiple viral systems (HIV, Ebola, etc.) to establish mechanism conservation

  • Include TSG101-depleted cells as controls

  • Consider TSG101 mutations that specifically disrupt viral late domain interactions

What are best practices for using TSG101 antibodies in multi-color flow cytometry of extracellular vesicles?

Flow cytometric analysis of extracellular vesicles using TSG101 antibodies requires specific optimizations:

• Sample preparation:

  • Purify extracellular vesicles using differential ultracentrifugation or size exclusion chromatography

  • Permeabilize vesicles to access intraluminal TSG101 epitopes (0.1% saponin recommended)

• Antibody selection and labeling:

  • Choose directly conjugated TSG101 antibodies when available (PE or FITC conjugates)

  • For indirect labeling, select secondary antibodies with minimal spectral overlap with other fluorophores

  • Titrate antibody concentrations to determine optimal signal-to-noise ratio

• Panel design considerations:

  • Include membrane markers (CD63, CD9, CD81) with distinct fluorophores

  • Add annexin V to identify phosphatidylserine-positive vesicles

  • Consider additional cargo markers depending on research question

• Instrument optimization:

  • Use fluorescent beads of known size (100nm, 500nm, 1μm) for calibration

  • Optimize forward and side scatter thresholds to detect extracellular vesicle populations

  • Consider dedicated small particle analyzers for vesicles <200nm

• Controls and validation:

  • Include fluorescence-minus-one (FMO) controls for each channel

  • Use isotype controls at the same concentration as TSG101 antibodies

  • Include detergent-treated samples as negative controls (disrupts vesicle integrity)

  • Verify flow cytometry results with orthogonal methods (Western blot, electron microscopy)

How does TSG101 protein function interact with the ubiquitination pathway in research applications?

TSG101's role in recognizing ubiquitinated cargo creates unique research considerations:

• Detection of TSG101-ubiquitin interactions:

  • Co-immunoprecipitation using TSG101 antibodies followed by ubiquitin detection

  • Proximity ligation assays between TSG101 and ubiquitin

  • FRET/BRET approaches using labeled TSG101 antibody fragments and ubiquitin

• Experimental variables affecting detection:

  • Proteasome inhibitors (MG132, bortezomib) can alter the pool of ubiquitinated TSG101 substrates

  • Deubiquitinating enzyme inhibitors enhance detection of transient ubiquitination events

  • Cell lysis conditions must preserve ubiquitin linkages (include DUB inhibitors like N-ethylmaleimide)

• Investigation of ubiquitin-dependent cargo sorting:

  • Mutation of TSG101's ubiquitin-binding domain (UEV) disrupts cargo recognition

  • Comparative immunoprecipitation with wild-type versus UEV-mutant TSG101

  • Immunofluorescence co-localization between TSG101 and ubiquitinated cargo proteins

• Technical considerations:

  • Antibodies targeting different TSG101 domains may differentially detect ubiquitin-bound versus free TSG101

  • High background in ubiquitin co-IP experiments can be reduced by using tandem ubiquitin-binding entities (TUBEs)

  • RIPA buffer can disrupt some ubiquitin-dependent TSG101 interactions; consider milder lysis buffers

What are common troubleshooting strategies for weak or absent TSG101 signal in Western blots?

When encountering weak or absent TSG101 signal in Western blots, consider these methodological solutions:

• Sample preparation issues:

  • Increase protein loading (try 20-50μg total protein)

  • Use fresh protease inhibitors in lysis buffer

  • Avoid repeated freeze-thaw cycles of samples

• Transfer optimization:

  • Extend transfer time (90-120 minutes) for complete protein transfer

  • Use PVDF membranes instead of nitrocellulose for higher protein binding capacity

  • Verify transfer efficiency with reversible staining (Ponceau S)

• Antibody optimization:

  • Try higher antibody concentration (1:500 instead of 1:1000)

  • Extend primary antibody incubation (overnight at 4°C)

  • Test alternative TSG101 antibody clones targeting different epitopes

• Detection enhancement:

  • Use high-sensitivity ECL substrate

  • Consider signal amplification systems

  • Increase exposure time incrementally

  • Try fluorescent secondary antibodies and imaging systems

• Sample-specific considerations:

  • For exosomal TSG101, increase starting material volume

  • For certain cell types with low TSG101 expression, consider enrichment by immunoprecipitation before Western blot

  • Verify protein extraction efficiency from difficult samples (tissues, exosomes)

How can I validate the specificity of a new TSG101 antibody?

Comprehensive validation of new TSG101 antibodies should follow these steps:

• Knockdown/knockout validation:

  • Perform siRNA/shRNA knockdown of TSG101

  • Use CRISPR/Cas9 TSG101 knockout cells as negative controls

  • Compare signal intensity reduction with reduction in TSG101 mRNA levels

• Overexpression validation:

  • Express tagged TSG101 constructs (Flag, HA, or GFP-tagged)

  • Confirm co-detection with tag-specific antibodies

  • Compare molecular weight with endogenous TSG101

• Peptide competition:

  • Pre-incubate antibody with immunizing peptide/protein

  • Confirm signal elimination with specific peptide but not irrelevant peptides

  • Use gradually increasing concentrations of competing peptide to establish specificity

• Cross-reactivity assessment:

  • Test across multiple species if cross-reactivity is claimed

  • Evaluate in multiple cell lines with varying TSG101 expression levels

  • Check for non-specific bands of unexpected molecular weights

• Multi-application testing:

  • Validate across different applications (WB, IP, IF, IHC)

  • Compare performance with established TSG101 antibodies

  • Document optimal conditions for each application

Literature reports indicate successful validation using siRNA knockdown with signal reduction corresponding to approximately 80-90% decrease in TSG101 signal intensity by Western blot .

What is the optimal protocol for immunoprecipitation of TSG101 and its binding partners?

For efficient TSG101 immunoprecipitation and co-immunoprecipitation, follow this optimized protocol:

• Lysis buffer selection:

  • Use mild NP-40 buffer (1% NP-40, 150mM NaCl, 50mM Tris-HCl pH 7.5)

  • Add protease inhibitors, phosphatase inhibitors, and 10mM N-ethylmaleimide

  • Include 5mM EDTA to disrupt metal-dependent interactions

  • For detecting weaker interactions, consider chemical crosslinking before lysis

• Pre-clearing step:

  • Incubate lysate with Protein A/G beads (25μl) for 1 hour at 4°C

  • Remove beads by centrifugation (1000×g, 5 minutes)

  • This reduces non-specific binding

• Immunoprecipitation:

  • Use 2-5μg TSG101 antibody per 500μg-1mg protein lysate

  • Incubate overnight at 4°C with gentle rotation

  • Add 30-50μl Protein A/G beads, incubate 2-4 hours at 4°C

  • For agarose-conjugated TSG101 antibodies, incubate directly with lysate

• Washing:

  • Perform 4-5 washes with lysis buffer containing reduced detergent (0.1% NP-40)

  • For the final wash, use detergent-free buffer to remove residual detergent

• Elution options:

  • Denaturing: Boil in SDS sample buffer (95°C, 5 minutes)

  • Native: Elute with excess immunizing peptide

  • Acid elution: 0.1M glycine pH 2.5, neutralize immediately with 1M Tris pH 8.0

• Controls:

  • Input sample (5-10% of starting material)

  • IgG control immunoprecipitation

  • Reverse co-IP to confirm interaction